<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02748876</url>
  </required_header>
  <id_info>
    <org_study_id>113</org_study_id>
    <nct_id>NCT02748876</nct_id>
  </id_info>
  <brief_title>Effect of His-Ventricular (HV) Interval Optimisation in Cardiac Resynchronisation Therapy</brief_title>
  <official_title>A Randomised Cross-over Pilot Study of the Effect of His-Ventricular (HV) Interval Optimisation in Cardiac Resynchronisation Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hull University Teaching Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hull University Teaching Hospitals NHS Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiac resynchronisation therapy (CRT) is a specialised type of pacemaker used in patients
      with severe heart failure to improve symptoms and survival. Approximately one third of
      patients treated with CRT do not notice significant improvement in their symptoms and this
      may be due to inadequate co-ordination between the upper and lower chambers of the heart
      (atrioventricular dyssynchrony).

      The investigators propose a new method to achieve atrioventricular synchrony in CRT based on
      measurements of electrical conduction from within the heart. Patients referred for CRT
      implantation at Castle Hill Hospital are eligible to participate. During CRT implantation,
      additional measurements, will be recorded from within the heart. After implantation, device
      settings will be adjusted to either standard or electrophysiologically-optimised settings
      with cross-over at 4 months.

      The investigators hypothesis is that patients with optimised settings will derive additional
      benefit compared to patients with standard pacemaker-determined settings.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 29, 2016</start_date>
  <completion_date type="Actual">March 15, 2018</completion_date>
  <primary_completion_date type="Actual">April 28, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in amino-terminal pro-B-type natriuretic peptide (NT-proBNP)</measure>
    <time_frame>7 months and 11 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Increase in 6-min walk test distance by ≥25 m</measure>
    <time_frame>7 months and 11 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>≥5points improvement in the short Kansas City Cardiomyopathy Questionnaire score</measure>
    <time_frame>7 months and 11 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of left ventricular end-diastolic volume.</measure>
    <time_frame>7 months and 11 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>His-Ventricular (HV)-optimised</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>His-Ventricular (HV) optimised atrioventricular delay</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-optimised</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard atrioventricular delay</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>His-Ventricular (HV) optimisation</intervention_name>
    <description>Optimisation of atrioventricular pacing interval</description>
    <arm_group_label>His-Ventricular (HV)-optimised</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of heart failure

          -  Referred for cardiac resynchronisation therapy (CRT) with or without defibrillator

          -  In sinus rhythm

          -  Patients must have a telephone

          -  Ability to give informed consent

          -  Ability to complete the study

        Exclusion Criteria:

          -  Severe valve disease or previous valve replacement

          -  Previous atrial flutter ablation

          -  Chronic kidney disease Stage 3 or above

          -  Recent myocardial infarction

          -  Ongoing cardiac ischaemia

          -  Infiltrative cardiomyopathy

          -  Wolff-Parkinson White syndrome

          -  Presence of second or third degree heart block

          -  &lt;90% biventricular pacing at 3 months

          -  Hypertrophic cardiomyopathy

          -  Pregnancy or breastfeeding

          -  On treatment for hypothyroidism or hyperthyroidism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Castle Hill Hospital</name>
      <address>
        <city>Hull</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>April 20, 2016</study_first_submitted>
  <study_first_submitted_qc>April 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2016</study_first_posted>
  <last_update_submitted>July 15, 2019</last_update_submitted>
  <last_update_submitted_qc>July 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

